Clinical Trials & Translational Studies in Scleroderma

 

Actively Recruiting Clinical Trials

Study Name

Indication

Principal Investigator

Study Contact

Email/Phone

Rilonacept- Randomized, Double-Blind,
Placebo-Controlled Trial of IL1-TRAP –
A Phase I/II Biomarker Trial
Diffuse SSc Robert Lafyatis, MD Jessica Ziemek jziemek@bu.edu

617.638.5383

LOTUSS Study – Pirfenidone in
Scleroderma-associated
Interstitial Lung Disease
Diffuse & Limited

SSc

Robert Simms, MD Britte Zlatanova

Kim Finch

Fei-Ying Cheong

 

britte@bu.edu

kimtobin.edu

fycheong.edu

 

Quantification of Septal Thickening in
Scleroderma Patients Utilizing Hyperpolarized
129Xe MRI
SSc with ILD Robert Lafyatis Fei-Ying Cheong fycheong@bu.edu

617.638.4344

Pomalidomide in Diffuse SSc with ILD Diffuse SSc with ILD Robert Simms, MD Eric Stratton

Fei-Ying Cheong

eas@bu.edu

fycheong@bu.edu

A Randomized, Double-Blind, Placebo-
Controlled, Phase II Multi-Center Trial of a
Monoclonal Antibody to CD20 (Rituxamab)
For the Treatment of Systemic Sclerosis-
Associated Pulmonary Arterial Hypertension
Harrison Farber, MD

Robert Simms, MD

Eric Stratton

Fei-Ying Cheong

eas@bu.edu
IKARIA A Phase 2,
Placebo Controlled,
Double-Blind, Randomized, Clinical
Study To Determine Safety,Tolerability
and Efficacy of Pulsed, Inhaled Nitric
Oxide (iNO) Versus Placebo As Add-On
Therapy in Symptomatic Subjects with
Pulmonary Arterial Hypertension (PAH)
PAH Harrison Farber, MD Fei-Ying Cheong fycheong@bu.edu

617.638.4344

SYMPHONY- A Multi-center, Open Label,
Single-arm, Phase 3b Study of
Macitentan in Patients with
Pulmonary Arterial Hypertension
to psychometrically validate the
PAH-SYMPACT instrument
PAH Harrison Farber, MD Kim Finch kimtobin@bu.edu

617.638.4475

Actively Recruiting Translational Studies

Fibroblast and Immune Cell
Culture From Skin
Diffuse SSc Robert Lafyatis, MD Jessica Ziemek jziemek@bu.edu

617.638.5383

CORT Biomarker Study SSc Robert Lafyatis, MD Eric Stratton eas@bu.edu

 

 

 

BU_SclerodermaLogoFnl_SMALL